Brief: Alkermes Initiates Artistry-7 Phase 3 Trial Of Nemvaleukin Alfa In Patients With Platinum-Resistant Ovarian Cancer
26/10/2021 13:25
Oct 26 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES INITIATES ARTISTRY-7 PHASE 3 TRIAL OF NEMVALEUKIN
ALFA
IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
Source text for Eikon: ID:nPn8KhGDfa
Further company coverage: ALKS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million